Tilt Biotherapeutics
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2024-09-01attributed |
| Founded | unknown |
| Headquarters | Helsinki, Finland |
| Industry | biotech |
| Stage | unknown |
| Website | tiltbio.com |
TILT Biotherapeutics develops oncolytic immunotherapies using engineered viruses delivered intravenously to make cold tumors responsive to the immune system. It targets solid-tumor patients who have not responded to existing immunotherapies. Its lead virus is armed with two cytokines, TNF and IL-2, unlike single-payload approaches.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-09-01 | grant | $2.7M | undisclosed |
Detected tech stack
Nginx, PHP, Typekit, Adobe Fonts, jQuery CDN, WordPress, MySQL, jquery 3.1.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | tiltbio.com, read 2026-05-08 |
| Description | self-reported | tiltbio.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.